UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549

                                   FORM 10-QSB


(Mark One)

/X/   QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
      EXCHANGE ACT OF 1934

      FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2004.

                                       OR

/ /   TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT
      OF 1934

      FOR THE TRANSITION FROM _______ TO ________.


                         COMMISSION FILE NUMBER 0-29531


                         ADVANCED MEDICAL INSTITUTE INC.
        _________________________________________________________________
        (Exact Name of Small Business Issuer as Specified in its Charter)


            NEVADA                                               88-0409144
_______________________________                              ___________________
(State or other jurisdiction of                               (I.R.S. Employer
 incorporation or organization)                              Identification No.)


  6767 W. Tropicana Avenue, Suite 207
         Las Vegas, Nevada                                              89103
________________________________________                              __________
(Address of principal executive offices)                              (Zip code)


                   Issuer's telephone number: (702) 248-1027


                   ___________________________________________
                     (Former name, former address and former
                   fiscal year, if changed since last report.)


Indicate by check mark whether the registrant (1) has filed all reports required
to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during
the preceding 12 months (or for such shorter period that the registrant was
required to file such reports), and (2) has been subject to such filing
requirements for the past 90 days. Yes /X/ No / /


                                      -1-


<PAGE>


Indicate  by check mark  whether  the  registrant  is an  accelerated  filer (as
defined in Rule 12b-2 of the Exchange Act). Yes / / No /X/


State the number of shares outstanding of each of the issuer's classes of common
equity, for the period covered by this report and as at the latest practicable
date:

     At September 30, 2004, and as of the date hereofe, there were outstanding
     2,100,000 shares of the Registrant's Common Stock, $.001 par value.


Transitional Small Business Disclosure Format: Yes / /   No /X/


                                      -2-


<PAGE>


                                     PART I

                              FINANCIAL INFORMATION


ITEM 1.   FINANCIAL STATEMENTS







                         ADVANCED MEDICAL INSTITUTE INC.
                          (A Development Stage Company)

                                FINANCIAL REPORTS

                               SEPTEMBER 30, 2004
                                DECEMBER 31, 2003




<PAGE>




                         ADVANCED MEDICAL INSTITUTE INC.
                          (A DEVELOPMENT STAGE COMPANY)

                                    CONTENTS




________________________________________________________________________________

FINANCIAL STATEMENTS

   Balance Sheets                                                            F-1

   Statements of Income                                                      F-2

   Statements of Stockholders' Equity                                        F-3

   Statements of Cash Flows                                                  F-4

   Notes to Financial Statements                                           F-5-9

________________________________________________________________________________




<PAGE>

<TABLE>
<CAPTION>


                        ADVANCED MEDICAL INSTITUTE, INC.
                          (A DEVELOPMENT STAGE COMPANY)
                                 BALANCE SHEETS

                                                       September 30,       December 31,
                                                                2004               2003
                                                       _____________       ____________
<S>                                                      <C>                 <C>


                                     ASSETS

CURRENT ASSETS                                           $      0            $      0
                                                         ________            ________

         Total current assets                            $      0            $      0
                                                         ________            ________

            Total assets                                 $      0            $      0
                                                         ========            ========


                      LIABILITIES AND STOCKHOLDERS' EQUITY

CURRENT LIABILITIES
   Accounts payable                                      $      0            $    255
   Officers advances (Note 7)                              39,163              32,301
                                                         ________            ________

         Total current liabilities                       $ 39,163            $ 32,556
                                                         ________            ________


STOCKHOLDERS' EQUITY
   Common stock: $.001 par value;
      authorized 25,000,000 shares;
      issued and outstanding:
      2,100,000 shares at December 31, 2003:             $                   $  2,100
      2,100,000 shares at September 30, 2004;               2,100
   Additional Paid In Capital                                   0                   0
   Accumulated deficit during development stage           (41,263)            (34,656)
                                                         ________            ________

         Total stockholders' equity                      $(39,163)           $(32,556)
                                                         ________            ________

            Total liabilities and
            stockholders' equity                         $      0            $      0
                                                         ========            ========


                 See Accompanying Notes to Financial Statements.

</TABLE>


                                      F-1


<PAGE>

<TABLE>
<CAPTION>


                        ADVANCED MEDICAL INSTITUTE, INC.
                          (A DEVELOPMENT STAGE COMPANY)
                              STATEMENTS OF INCOME


                                                                                                            Dec. 6, 1996
                                           Nine months ended                     Years Ended              (inception) to
                                    September 30,     September 30,     December 31,     December 31,      September 30,
                                             2004              2003             2003             2002               2004
                                    _____________     _____________     ____________     ____________     ______________
<S>                                  <C>               <C>               <C>              <C>               <C>

Revenues                             $        0        $        0        $        0       $        0        $        0

Cost of revenue                               0                 0                 0                0                 0
                                     __________        __________        __________       __________        __________

      Gross profit                   $        0        $        0        $        0       $        0        $        0

General, selling and
   administrative expenses                6,607                 0                85            2,716            41,263
                                     __________        __________        __________       __________        __________
      Operating (loss)               $   (6,607)       $       (0)       $      (85)      $   (2,716)       $  (41,263)

Nonoperating income (expense)                 0                 0                 0                0                 0
                                     __________        __________        __________       __________        __________

   Net (loss)                        $   (6,607)       $       (0)       $      (85)      $   (2,716)       $  (41,263)
                                     ==========        ==========        ==========       ==========        ==========


   Net (loss) per share, basic
   and diluted (Note 2)              $    (0.00)       $    (0.00)       $    (0.00)      $    (0.00)       $    (0.02)
                                     ==========        ==========        ==========       ==========        ==========

   Average number of shares
   of common stock outstanding        2,100,000         2,100,000         2,100,000        2,100,000         2,100,000
                                     ==========        ==========        ==========       ==========        ==========


                 See Accompanying Notes to Financial Statements.

</TABLE>

                                      F-2


<PAGE>

<TABLE>
<CAPTION>


                        ADVANCED MEDICAL INSTITUTE, INC.
                          (A DEVELOPMENT STAGE COMPANY)
                       STATEMENTS OF STOCKHOLDERS' EQUITY


                                                                                                            Accumulated
                                                                                                             (Deficit)
                                                               Common Stock               Additional          During
                                                       ____________________________        Paid-In          Development
                                                         Shares            Amount          Capital             Stage
                                                       __________        __________       __________        ___________
<S>                                                     <C>              <C>              <C>               <C>

Balance, December 31, 1998                              2,100,000        $    2,100       $        0        $   (2,100)

November 29, 1999, changed from no
    par value to $.001                                                       (2,079)           2,079

November 29, 1999, forward stock
    100:1                                                                     2,079           (2,079)

Net (loss), December 31, 1999                                                                                     (350)
                                                       __________        __________       __________        __________

Balance, December 31, 1999                              2,100,000        $    2,100       $        0        $   (2,450)

Net (loss), December 31, 2000                                                                                  (24,677)
                                                       __________        __________       __________        __________

Balance, December 31, 2000                              2,100,000        $    2,100       $        0        $  (27,127)

Net (loss), December 31, 2001                                                                                   (4,728)
                                                       __________        __________       __________        __________

Balance, December 31, 2001                              2,100,000        $    2,100       $        0        $  (31,855)

Net (loss), December 31, 2002                                                                                   (2,716)
                                                       __________        __________       __________        __________

Balance, December 31, 2002                              2,100,000        $    2,100       $        0        $  (34,571)

Net (loss), December 31, 2003                                                                                      (85)
                                                       __________        __________       __________        __________

Balance, December 31, 2003                              2,100,000        $    2,100       $        0        $  (34,656)

Net (loss) January 1, 2004 to
September 30, 2004                                                                                              (6,607)
                                                       __________        __________       __________        __________

Balance, September 30, 2004                             2,100,000        $    2,100       $        0        $  (41,263)
                                                       ==========        ==========       ==========        ==========


                 See Accompanying Notes to Financial Statements.

</TABLE>


                                       F-3


<PAGE>

<TABLE>
<CAPTION>


                        ADVANCED MEDICAL INSTITUTE, INC.
                          (A DEVELOPMENT STAGE COMPANY)
                            STATEMENTS OF CASH FLOWS


                                                                                                            Dec. 6, 1996
                                           Nine months ended                     Years Ended              (inception) to
                                    September 30,     September 30,     December 31,     December 31,      September 30,
                                             2004              2003             2003             2002               2004
                                    _____________     _____________     ____________     ____________     ______________
<S>                                  <C>               <C>               <C>              <C>               <C>

Cash Flows From
Operating Activities
    Net (loss)                       $   (6,607)       $       (0)       $      (85)      $   (2,716)       $  (41,263)
    Adjustments to reconcile
    net (loss) to cash
    (used in) operating
    activities:
    Changes in assets
    and liabilities
    Increase in accounts payable           (255)                0                85               85                 0
                                     __________        __________        __________       __________        __________

         Net cash (used in)
            operating activities     $   (6,862)       $        0        $        0       $   (2,631)       $  (41,263)
                                     __________        __________        __________       __________        __________

Cash Flows From
Investing Activities                 $        0        $        0        $        0       $        0        $        0
                                     __________        __________        __________       __________        __________

Cash Flows From
Financing Activities
    Increase in officer advances          6,862                 0                 0            2,631            39,163
    Issuance of common stock                  0                 0                 0                0             2,100
                                     __________        __________        __________       __________        __________

         Net cash (used in)
            financing activities     $    6,862        $        0        $        0       $    2,631        $   41,263
                                     __________        __________        __________       __________        __________

         Net increase (decrease)
            in cash                  $        0        $        0        $        0       $        0        $        0

Cash, beginning of period                     0                 0                 0                0                 0
                                     __________        __________        __________       __________        __________
Cash, end of period                  $        0        $        0        $        0       $        0        $        0
                                     ==========        ==========        ==========       ==========        ==========


                 See Accompanying Notes to Financial Statements.

</TABLE>

                                      F-4


<PAGE>



                        ADVANCED MEDICAL INSTITUTE, INC.
                          (A DEVELOPMENT STAGE COMPANY)
                          NOTES TO FINANCIAL STATEMENTS
                    SEPTEMBER 30, 2004, AND DECEMBER 31, 2003


NOTE 1.  NATURE OF BUSINESS AND SIGNIFICANT ACCOUNTING POLICIES

NATURE OF BUSINESS:

Advanced Medical Institute Inc.,  formerly  Hawksdale  Financial  Visions,  Inc.
("Company"),  was  organized  December  6,  1996  under the laws of the State of
Nevada.  The  Company  currently  has no  operations  and,  in  accordance  with
Statement  of  Financial  Accounting  Standard  (SFAS)  No. 7,  "ACCOUNTING  AND
REPORTING BY DEVELOPMENT  STAGE  ENTERPRISES," is considered a development stage
company.

A SUMMARY OF THE COMPANY'S SIGNIFICANT ACCOUNTING POLICIES IS AS FOLLOWS:

ESTIMATES

The preparation of financial  statements in conformity  with generally  accepted
accounting principles requires management to make estimates and assumptions that
affect  the  reported  amounts  of assets  and  liabilities  and  disclosure  of
contingent  assets and  liabilities at the date of the financial  statements and
the  reported  amounts of revenues  and expenses  during the  reporting  period.
Actual results could differ from those estimates.

CASH

For the Statements of Cash Flows, all highly liquid investments with maturity of
three months or less are considered to be cash  equivalents.  There were no cash
equivalents as of September 30, 2004 and 2003, and December 31, 2003 and 2002.

INCOME TAXES

Income  taxes are  provided  for using the  liability  method of  accounting  in
accordance with SFAS No. 109 "ACCOUNTING FOR INCOME TAXES." A deferred tax asset
or liability is recorded for all temporary differences between financial and tax
reporting.  Temporary  differences  are the  differences  between  the  reported
amounts of assets and liabilities  and their tax basis.  Deferred tax assets are
reduced by a valuation allowance when, in the opinion of management,  it is more
likely than not that some  portion or all of the deferred tax assets will not be
realized.  Deferred  tax assets and  liabilities  are adjusted for the effect of
changes in tax laws and rates on the date of enactment.

GOING CONCERN

The Company's  financial  statements  are prepared in accordance  with generally
accepted accounting  principles applicable to a going concern. This contemplates
the  realization  of assets and the  liquidation  of  liabilities  in the normal
course of business.  Currently,  the Company does not have  significant  cash or
other  material  assets,  nor does it have  operations  or a source  of  revenue
sufficient  to cover its  operation  costs and allow it to  continue  as a going
concern.  The  officers  and  directors  have  committed  to  advancing  certain
operating costs of the Company.


                                      F-5


<PAGE>


                        ADVANCED MEDICAL INSTITUTE, INC.
                          (A DEVELOPMENT STAGE COMPANY)
                          NOTES TO FINANCIAL STATEMENTS
                    SEPTEMBER 30, 2004, AND DECEMBER 31, 2003


NOTE 1. NATURE OF BUSINESS AND SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)
NEW ACCOUNTING PRONOUNCEMENTS

In  January  2003,  the  Financial   Accounting   Standards  Board  issued  FASB
Interpretation  No. 46,  Consolidation of Variable Interest Entities ("FIN 46").
Under  that  interpretation,   certain  entities  known  as  "Variable  Interest
Entities:  ("VIE")  must be  consolidated  by the "primary  beneficiary"  of the
entity.  The primary  beneficiary is generally defined as having the majority of
the risks and rewards  arising  from the VIE.  For VIE's in which a  significant
(but not majority) variable interest if held, certain  disclosures are required.
FIN 46 requires disclosure of Variable Interest Entities in financial statements
issued  after  January 31, 2003,  if it is  reasonably  possible  that as of the
transaction date: (1) the Company will be the primary beneficiary of an existing
VIE that will require  consolidation  or (2) the Company will hold a significant
variable interest in, or have significant involvement with, an existing VIE. Any
VIE's  created  after  January  31,  2003,  are   immediately   subject  to  the
consolidation   guidance  in  FIN  46.  The   measurement   principles  of  this
interpretation  will be effective for the Company's 2003  financial  statements.
The  Company  does  not  have  any  entities  that  require  disclosure  or  new
consolidation as a result of adopting the provisions of FIN 46.

In April 2003,  the FASB issued SFAS No. 149,  "Amendment  of  Statement  133 on
Derivative  Instruments  and  Hedging  Activities."  The  Statement  amends  and
clarifies  accounting for derivative  instruments,  including certain derivative
instruments  embedded in other contracts,  and for hedging activities under SFAS
No. 133. SFAS No. 149 is effective for contracts  entered into of modified after
June 30, 2003, for hedging relationships  designated after June 30, 2003, and to
certain  preexisting  contracts.  We  adopted  SFAS No. 149 on July 1, 2003 on a
prospective basis in accordance with the new statement. The adoption of SFAS No.
149 did not have a  material  impact on our  financial  condition  or results of
operations.

In May 2003,  the FASB issued SFAS No. 150,  "Accounting  for Certain  Financial
Instruments with Characteristics of both Liabilities and Equity." This Statement
establishes  standards  for  how  an  issuer  classifies  and  measures  certain
financial  instruments with characteristics of both liabilities and equity. SFAS
No. 150 requires that an issuer  classify a financial  instrument that is within
its scope as a  liability  or,  in some  circumstances,  as an asset,  with many
financial  instruments having been classified as equity. We adopted SFAS No. 150
on July 1, 2003. The FASB is addressing certain implementation issues associated
with the application of SFAS No. 150. In October 2003, the FASB decided to defer
certain provisions of SFAS No. 150 related to mandatorily  redeemable  financial
instruments  non-controlling  interests in subsidiaries included in consolidated
financial  statements.  The  adoption  of SFAS No.  150 did not have a  material
impact on our financial condition or results of operation.

In November  2003,  the EITF reached a consensus on Issue 03-01,  THE MEANING OF
OTHER-THAN-TEMPORARY IMPAIRMENT AND ITS APPLICATION TO CERTAIN INVESTMENTS (EITF
03-01).  EITF 03-01  establishes  additional  disclosure  requirements  for each
category of FAS 115  investments in a loss position.  Effective for years ending
after  December 15,  2003,  companies  must  disclose  the  aggregate  amount of
unrealized  losses,  and the aggregate  related fair value of their  investments
with unrealized losses. Those investments are required to be segregated by those
in a loss position for less than 12 months and those in a loss position  greater
than 12 months. Additionally,  certain qualitative disclosures should be made to
clarify a circumstance  whereby an investment's fair value that is below cost is
not considered  other  -than-temporary.  The provisions of this consensus do not
have a significant effect on our financial position or operating results.


                                      F-6


<PAGE>


                        ADVANCED MEDICAL INSTITUTE, INC.
                          (A DEVELOPMENT STAGE COMPANY)
                          NOTES TO FINANCIAL STATEMENTS
                    SEPTEMBER 30, 2004, AND DECEMBER 31, 2003


NOTE 1. NATURE OF BUSINESS AND SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

NEW ACCOUNTING PRONOUNCEMENTS

In November  2003,  the EITF reached a consensus on Issue 03-10.  APPLICATION OF
EITF  02-16  BY   RESELLERS  TO  SALES   INCENTIVES   OFFERED  TO  CONSUMERS  BY
MANUFACTURERS,  addressing  how a reseller  is to account  for  redemption  of a
manufacturer's  coupon by a consumer at the  reseller's  location  (EITF 03-10).
EITF 03-10 eliminates the option that permitted resellers to report the value of
the  consideration  received  as a reduction  in cost of goods sold,  but rather
mandates  that it be  recorded  as  revenue.  EITF  03-10 is  applicable  to new
arrangements,  including modifications to existing arrangements, entered into in
fiscal  periods after November 25, 2003. The provisions of this consensus do not
have a significant effect on our financial position or operating results.

In  December  2003,  the FASB  issued SFAS No. 132  (revised  2003),  EMPLOYERS'
DISCLOSURE  ABOUT  PENSIONS  AND OTHER  POSTRETIREMENT  BENEFITS.  SFAS No.  132
(revised  2003)  revises  employers'  disclosure  about  pension plans and other
postretirement  benefit plans.  The statement does not change the measurement or
recognition  of those plans required by SFAS No. 87,  EMPLOYERS'  ACCOUNTING FOR
PENSIONS, SFAS No. 88, EMPLOYERS' ACCOUNTING FOR SETTLEMENTS AND CURTAILMENTS OF
DEFINED BENEFIT PENSION PLANS AND FOR  TERMINATION  BENEFITS,  and SFAS No. 106,
EMPLOYERS'  ACCOUNTING FOR  POSTRETIREMENT  BENEFITS  OTHER THAN  PENSIONS.  The
Revised statement retains the disclosure  requirements contained in the original
SFAS 132 and requires additional disclosures about the assets, obligations, cash
flows,  and net periodic benefit cost of defined benefit pension plans and other
defined benefit  postretirement  plans.  The revised  statement is effective for
fiscal  years  ending  after  December  15,  2003.  The adoption of SFAS No. 132
(revised)  did not have an impact  on our  financial  condition  or  results  of
operations.

NOTE 2.  STOCKHOLDERS' EQUITY

COMMON STOCK

The authorized  common stock of the Company  consists of 25,000,000  shares with
par value of $0.001.  On December 10, 1996,  the Company issued 21,000 shares of
its no par value common stock in consideration of $2,100 in cash.

On November 29, 1999, the Company's shareholders approved a forward split of its
common stock at one hundred shares for one share of the existing shares.

On November 29, 1999,  the State of Nevada  approved the Company's  Amendment to
the Articles of Incorporation,  which increased its  capitalization  from 25,000
common  shares to  25,000,000  common  shares.  The no par value was  changed to
$0.001 per share. The number of common stock shares  outstanding  increased from
21,000 to 2,100,000.  Prior period  information has been restated to reflect the
stock split

On October 15, 2004, the Company's name was changed to Advance Medical Institute
Inc., when the Company merged a susidiary into itself.

The Company has not authorized any preferred stock.


                                      F-7


<PAGE>


                        ADVANCED MEDICAL INSTITUTE, INC.
                          (A DEVELOPMENT STAGE COMPANY)
                          NOTES TO FINANCIAL STATEMENTS
                    SEPTEMBER 30, 2004, AND DECEMBER 31, 2003


NOTE 2.      STOCKHOLDERS' EQUITY (CONTINUED)

NET LOSS PER COMMON SHARE

Net loss per share is calculated in accordance with SFAS No. 128,  "EARNINGS PER
SHARE." The  weighted-average  number of common shares  outstanding  during each
period  is used to  compute  basic  loss per  share.  Diluted  loss per share is
computed  using the weighted  averaged  number of shares and dilutive  potential
common shares  outstanding.  Dilutive  potential  common  shares are  additional
common shares assumed to be exercised.

Basic  net loss per  common  share is based on the  weighted  average  number of
shares of common stock  outstanding of 2,100,000  during 2004,  2003,  2002, and
since inception.  As of December 31, 2003, 2002, 2001, and since inception,  the
Company had no dilutive potential common shares.

NOTE 3.  INCOME TAXES

We did not provided any current or deferred U.S.  federal  income tax provisions
or benefit  for any  periods  presented  because we have  experienced  operating
losses  since  inception.  We  provided a full  valuation  allowance  on the net
deferred tax asset,  consisting of net  operating  loss  carryforwards,  because
management  has  determined  that it is more  likely  than not that we will earn
income  sufficient  to realize the deferred tax assets  during the  carryforward
period.

The  Components of the Company's  deferred tax asset as of December 31, 2003 and
2002 is as follows:

                                              2003            2002
                                            ________        ________

     Net operating loss carry forward       $ 12,129        $ 12,100
     Valuation allowance                    $(12,129)       $(12,100)
                                            ________        ________

     Net deferred tax asset                 $      0        $      0

A  reconciliation  of income taxes  computed at the statutory rate to the income
tax amount recorded is as follows:

                                                                         Since
                                              2003           2002      Inception
                                            ________       ________    _________

     Tax at statutory rate                  $     29       $    951    $ 12,129
     Increase in valuation allowance        $    (29)      $   (951)    (12,129)
                                            ________       ________    ________

     Net deferred tax asset                 $      0       $      0    $      0

The net federal  operating loss carry forward will expire between 2016 and 2022.
This  carry  forward  may  be  limited  upon  the  consummation  of  a  business
combination under IRC Section 381.


                                      F-8


<PAGE>


                        ADVANCED MEDICAL INSTITUTE, INC.
                          (A DEVELOPMENT STAGE COMPANY)
                          NOTES TO FINANCIAL STATEMENTS
                    SEPTEMBER 30, 2004, AND DECEMBER 31, 2003


NOTE 4.  RELATED PARTY TRANSACTIONS

The  Company  neither  owns  nor  leases  any  real or  personal  property.  The
registered  agent of the corporation  provides  office services  without charge.
Such costs are immaterial to the financial statements and accordingly,  have not
been reflected therein.  The officers and directors for the Company are involved
in other business  activities and may, in the future,  become  involved in other
business  opportunities.  If a specific business  opportunity becomes available,
such  persons  may face a conflict  in  selecting  between the Company and their
other  business  interest.  The  Company  has not  formulated  a policy  for the
resolution of such conflicts.

NOTE 5.  WARRANTS AND OPTIONS

There are no warrants or options outstanding to acquire any additional shares of
common stock of the Company.

NOTE 6.  OFFICERS ADVANCES

The Company has incurred  costs in connection  with its business  purpose and to
comply with the federal  securities laws. An officer of the Company has advanced
funds on behalf of the  Company to pay for these  costs.  These  funds have been
advanced interest free.


                                      F-9


<PAGE>

ITEM 2.   MANAGEMENT'S  DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND
          RESULTS OF OPERATIONS

     The discussion contained herein contains "forward-looking statements"  that
involve risk and uncertainties. These statements may be identified by the use of
terminology such as "believes," "expects," "may," "should" or anticipates" or
expressing this terminology negatively or similar expressions or by discussions
of strategy. The cautionary statements made in this Form 10QSB should be read as
being applicable to all related forward-looking statements wherever they appear
in this Form 10QSB. Our actual results could differ materially from those
discussed in this report.

Generally.

     On October 1, 2004, we caused to be formed a subsidiary corporation under
the laws of the State of Nevada called Advanced Medical Institute Inc. and on
October 15, 2004, we merged the corporation into us. As a result of the merger,
the corporate name was changed to "Advanced Medical Institute Inc."

     See the Articles of Merger in 9.01 of the Form 8-K filed on October 15,
2004.

     We currently have no assets or operations. Since March 31, 1997, we have
been in the developmental stage and have had no operations. We originally had
intended to time share a single family dwelling house in the Rum Cay area of the
Bahamas, offering a one-twelfth fractional interest. As at March 31, 1997, all
funds raised by the sale of shares of $.001 par value common stock in order to
fulfill our initial objective had been expended and we, thereafter, become
dormant.


Plan of Operation.

     The Company intends to seek to acquire assets or shares of an entity
actively engaged in business that generates revenues in exchange for its
securities.


                                      -3-


<PAGE>


     Our majority shareholders have had preliminary negotiations to effectuate a
business combination. These preliminary negotiations include adding new officers
and directors to our board.

     We have been informed that, if, pursuant to any arrangement or
understanding with the person or persons acquiring securities in a transaction
subject to the 1934 Act, any persons are to be elected or designated as
directors of the Company, otherwise than at a meeting of security holders, and
the persons so elected or designated will constitute a majority of the directors
of the Company, then, not less than 10 days prior to the date any such persons
take office as a director, or such shorter period prior to the date the
Securities and Exchange Commission may authorize upon a showing of good cause
therefore, the Company shall file with the Securities and Exchange Commission
and transmit to all holders of record of securities of the Company who would be
entitled to vote at a meeting for election of directors, information
substantially equivalent to certain information which would be required by
Schedule 14A of Regulation 14A to be transmitted if such person or persons were
nominees for election as directors at a meeting of such security holders.

     We have been informed that the Securities and Exchange Commission is
considering whether to propose amendments to the Form 8-S and the Form 8-K for
companies like us. The proposed amendments could expand the definition of a
shell company to be broader than a company with no or nominal operations/assets
or assets consisting of cash and cash equivalents, the amendments may prohibit
the use of a From S-8 (a form used by a corporation to register securities
issued to an employee, director, officer, consultant or advisor, under certain
circumstances), and may revise the Form 8-K to require a shell company to
include current Form 10 or Form 10-SB information, including audited financial
statements, in the filing on Form 8-K that the shell company files to report the
acquisition of the business opportunity.

     In the event of any business combination as a result the preliminary
negotiations referred to above, we intend to file a Form 8-K and comply with the
Securities Exchange Act of 1934, as amended.


                                      -4-


<PAGE>


Financial Condition.

     Our auditor's going concern opinion for prior year ended and the notation
in the financial statements indicate that we do not have significant cash or
other material assets and that we are relying on advances from stockholders,
officers and directors to meet limited operating expenses.

Liquidity and Operational Results.

     We have no current operating history and we do not have any revenues or
earnings from operations. We have no assets or financial resources and we will,
in all likelihood, sustain operating expenses without corresponding revenues, at
least until the consummation of the business combination.

     We are dependent upon our officers to meet any de minimis costs that may
occur. Christina Escobedo, an officer and director of the Company, has agreed to
provide the necessary funds, without interest, for us to comply with the
Securities Exchange Act of 1934, as amended; provided that she is an officer and
director of the Company when the obligation is incurred. All advances are
interest-free.

Liquidity.

     As of September 30, 2004, we had total liabilities of $39,163 and we had a
negative net worth of $39,163. As of December 31, 2003, we had total liabilities
of $32,556 and a negative net worth of $32,556. Our total liabilities and our
negative net worth each increased by $6,607.

     We have had no revenues from inception through December 31, 2003 and we had
no revenues for the period ended September 30, 2004. We have a loss from
inception through December 31, 2003 of $34,656 and a loss from inception through
September 30, 2004 of $41,263. Our losses increased for the period ending
September 30, 2004 by $6,607.

     We have officer's advances of $39,163 from inception to September 30, 2004.
The officer's advances as of December 31, 2003 and March 31, 2004 were $32,301.
The officer's advances increased during the current quarter by 6,862. Our
accounts payable as of December 31, 2004 was $255 and as of September 30, 2004,
the accounts payable had be paid and had decreased by $255.


                                      -5-


<PAGE>


ITEM 3. QUALITATIVE AND QUANTITATIVE DISCLOSURES ABOUT MARKET RISK.

     We have not considered or conducted any research concerning qualitative and
quantitative market risk.

ITEM 4.  EVALUATION OF DISCLOSURE ON CONTROLS AND PROCEDURES.

     Based on an evaluation of our disclosure controls and procedures as of the
end of the period covered by this Form 10QSB (and the financial statements
contained in the report), our president and treasurer have determined that the
our current disclosure controls and procedures are effective.

     There have not been any changes in our internal control over financial
reporting (as such term is defined in Rule 13a-15(f) under the Exchange Act) or
any other factors during the quarter covered by this report, that have
materially affected, or are reasonably likely to materially affect our internal
control over financial reporting.


<PAGE>


                                     PART II

                                OTHER INFORMATION


Item 1 - Legal Proceedings .................................................None

Item 2 - Changes in the Rights of the Company's
         Security Holders ..................................................None

Item 3 - Defaults by the Company on its
         Senior Securities .................................................None

Item 4 - Submission of Matter to Vote of Security
         Holders ...........................................................None

Item 5 - Other Information

Board Meeting.

     Our board held three meetings during the period covered by this current
report.


                                      -6-


<PAGE>


Audit Committee.

     Our board of directors has not established an audit committee. In addition,
we do not have any other compensation or executive or similar committees. We
will not, in all likelihood, establish an audit committee until such time as the
Company generates a positive cash flow of which there can be no assurance.

     Until such time as an audit committee has been established, the full board
of directors will undertake those tasks normally associated with an audit
committee to include, but not by way of limitation, the (i) review and
discussion of the audited financial statements with management, and (ii)
discussions with the independent auditors the matters required to be discussed
by the Statement On Auditing Standards No. 61 and No. 90, as may be modified or
supplemented.

Stock Dividend.

     Effective as of the opening of business on November 8, 2004, our common
stock will be "forward split" because of a stock dividend on a 15 for 1 basis.
The effect is that there will be 16 shares held by each shareholder of record
(one original share and 15 additional shares. Prior to the record date,
1,450,000 shares held by our three directors will be surrendered for
cancellation. The then 650,000 outstanding shares will become 10,500,000 shares
of common stock. We have been informed by the officers and directors that
additional shares of stock may be required to be surrendered in the event that
the preliminary negotiations referred to above result in an agreement for a
business combination.

ITEM 6 - EXHIBITS AND REPORTS ON FORM 8-K

         A Form 8-K was filed on September 18, 2004

         31.1 Section 302 Certification - CEO

         31.2 Section 302 Certification - CFO

         32.1 Section 906 Certification - CEO

         32.2 Section 906 Certification - CFO


                                      -7-


<PAGE>


                                   SIGNATURES


     Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.



Dated:  November 5, 2004,           ADVANCED MEDICAL INSTITUTE, INC.


                                    By: /s/ CHRISTINA ESCOBEDO
                                        _________________________________
                                            Christina Escobedo
                                            President and Chief Executive
                                            Officer and Director


                                    By: /s/ THOMAS STANLEY BABCOCK
                                        _________________________________
                                            Thomas Stanley Babcock
                                            Treasurer and Chief Financial
                                            Officer and Director


                                    By: /s/ TRICIA A. WILLIS
                                        _________________________________
                                            Tricia A. Willis
                                            Director


                                      -8-